PURPOSE: Vasoactive intestinal peptide (VIP) is an anti-inflammatory neuropeptide that downregulates proinflammatory cytokines and promotes healing in a susceptible model of P. aeruginosa keratitis. Growth factors also play a role in corneal healing and restoration of tissue homeostasis after wounding. However, whether VIP treatment modulates growth factors to promote healing in the infected cornea remains untested and is the purpose of this study. METHODS: C57BL/6 (B6) mice were injected with VIP and mRNA and protein levels, and immunostaining for EGF, FGF, HGF, and VEGF-A were done. Exogenous treatment with a mixture of the growth factors also was tested and levels of cytokines, defensins, and bacterial counts were determined. RESULTS: Real-time RT-PCR, immunostaining, and ELISA data demonstrated that treatment with VIP enhanced levels of EGF, FGF, and HGF during disease, and that VEGF-A, and associated angiogenic molecules also were increased by VIP. Moreover, immunohistochemical studies confirmed that both epithelial and stromal cells participated in growth factor production. Most notably, treatment with a mixture of EGF, FGF, and HGF after disease onset, prevented corneal perforation when compared with controls. This outcome was associated with downregulation of proinflammatory cytokines such as macrophage inflammatory protein-2 (MIP-2), upregulation of anti-inflammatory cytokines such as TGF-β, and antimicrobials β-defensins 2 and 3, as well as decreased plate counts at 1 day postinfection (p.i.) (P = 0.0001). CONCLUSIONS: Collectively, the data provide evidence that VIP treatment modulates growth factors, angiogenic molecules, and defensins in the infected cornea and that this in turn promotes healing and restoration of tissue homeostasis.
PURPOSE: Vasoactive intestinal peptide (VIP) is an anti-inflammatory neuropeptide that downregulates proinflammatory cytokines and promotes healing in a susceptible model of P. aeruginosa keratitis. Growth factors also play a role in corneal healing and restoration of tissue homeostasis after wounding. However, whether VIP treatment modulates growth factors to promote healing in the infected cornea remains untested and is the purpose of this study. METHODS: C57BL/6 (B6) mice were injected with VIP and mRNA and protein levels, and immunostaining for EGF, FGF, HGF, and VEGF-A were done. Exogenous treatment with a mixture of the growth factors also was tested and levels of cytokines, defensins, and bacterial counts were determined. RESULTS: Real-time RT-PCR, immunostaining, and ELISA data demonstrated that treatment with VIP enhanced levels of EGF, FGF, and HGF during disease, and that VEGF-A, and associated angiogenic molecules also were increased by VIP. Moreover, immunohistochemical studies confirmed that both epithelial and stromal cells participated in growth factor production. Most notably, treatment with a mixture of EGF, FGF, and HGF after disease onset, prevented corneal perforation when compared with controls. This outcome was associated with downregulation of proinflammatory cytokines such as macrophage inflammatory protein-2 (MIP-2), upregulation of anti-inflammatory cytokines such as TGF-β, and antimicrobials β-defensins 2 and 3, as well as decreased plate counts at 1 day postinfection (p.i.) (P = 0.0001). CONCLUSIONS: Collectively, the data provide evidence that VIP treatment modulates growth factors, angiogenic molecules, and defensins in the infected cornea and that this in turn promotes healing and restoration of tissue homeostasis.
Authors: J C Tille; J Wood; S J Mandriota; C Schnell; S Ferrari; J Mestan; Z Zhu; L Witte; M S Pepper Journal: J Pharmacol Exp Ther Date: 2001-12 Impact factor: 4.030
Authors: N B Viget; B P Guery; F Ader; R Nevière; S Alfandari; C Creuzy; M Roussel-Delvallez; C Foucher; C M Mason; G Beaucaire; J F Pittet Journal: Am J Physiol Lung Cell Mol Physiol Date: 2000-12 Impact factor: 5.464
Authors: Thomas W Carion; Cody R McWhirter; Daiyajot K Grewal; Elizabeth A Berger Journal: Invest Ophthalmol Vis Sci Date: 2015-10 Impact factor: 4.799
Authors: Xiaoyu Jiang; Sharon A McClellan; Ronald Barrett; Megan Foldenauer; Linda D Hazlett Journal: Invest Ophthalmol Vis Sci Date: 2014-04-09 Impact factor: 4.799
Authors: Elizabeth A Berger; Kerry S Vistisen; Ronald P Barrett; Linda D Hazlett Journal: Invest Ophthalmol Vis Sci Date: 2012-11-01 Impact factor: 4.799
Authors: Xiaoyu Jiang; Sharon A McClellan; Ronald P Barrett; Yunfan Zhang; Megan E Foldenauer; Linda D Hazlett Journal: Invest Ophthalmol Vis Sci Date: 2012-11-07 Impact factor: 4.799
Authors: Haoshen Shi; Thomas W Carion; Youde Jiang; Jena J Steinle; Elizabeth A Berger Journal: Prostaglandins Other Lipid Mediat Date: 2016-03-26 Impact factor: 3.072
Authors: Cui Li; Yuan-Yuan Liu; Gui-Qiu Zhao; Jing Lin; Cheng-Ye Che; Nan Jiang; Na Li; Jie Zhang; Kun He; Xu-Dong Peng Journal: Int J Ophthalmol Date: 2018-02-18 Impact factor: 1.779